Erin X Wei1, Abrar A Qureshi2, Jiali Han3, Tricia Y Li4, Eunyoung Cho2, Jennifer Y Lin5, Wen-Qing Li6. 1. Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida. Electronic address: wei.erin@gmail.com. 2. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island; Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island. 3. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana; Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, Indiana. 4. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 5. Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 6. Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island; Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island.
Abstract
BACKGROUND: The incidence of melanoma in situ (MIS) is increasing, but little is known about its clinical and epidemiologic features. OBJECTIVE: We sought to determine trends in diagnosis and clinical features of MIS. METHODS: Incident cases of melanoma were collected prospectively from the Nurses' Health Study (1976-2010) and Health Professionals Follow-up Study (1986-2010). RESULTS: MIS incidence increased from 2 to 42 per 100,000 person-year among women, and from 11 to 73 per 100,000 person-year among men, exceeding the rate of increase of invasive melanomas. Melanoma mortality initially increased during the follow-up period then plateaued. Men were more likely than women to develop in situ melanomas on the upper half of the body (P < .001). Invasive melanomas were diagnosed at a younger age than MIS (P < .001), and were more likely to be found on the lower extremities than MIS (P < .001). LIMITATIONS: This is a strictly descriptive study without examination into mechanisms. CONCLUSION: We found epidemiologic and clinical differences for in situ and invasive melanomas, which support further examination into the variations in etiologic pathways. The lack of improvement in mortality despite the increase in detection of in situ relative to invasive lesions further highlights the need to improve invasive melanoma-specific clinical screening features.
BACKGROUND: The incidence of melanoma in situ (MIS) is increasing, but little is known about its clinical and epidemiologic features. OBJECTIVE: We sought to determine trends in diagnosis and clinical features of MIS. METHODS: Incident cases of melanoma were collected prospectively from the Nurses' Health Study (1976-2010) and Health Professionals Follow-up Study (1986-2010). RESULTS:MIS incidence increased from 2 to 42 per 100,000 person-year among women, and from 11 to 73 per 100,000 person-year among men, exceeding the rate of increase of invasive melanomas. Melanoma mortality initially increased during the follow-up period then plateaued. Men were more likely than women to develop in situ melanomas on the upper half of the body (P < .001). Invasive melanomas were diagnosed at a younger age than MIS (P < .001), and were more likely to be found on the lower extremities than MIS (P < .001). LIMITATIONS: This is a strictly descriptive study without examination into mechanisms. CONCLUSION: We found epidemiologic and clinical differences for in situ and invasive melanomas, which support further examination into the variations in etiologic pathways. The lack of improvement in mortality despite the increase in detection of in situ relative to invasive lesions further highlights the need to improve invasive melanoma-specific clinical screening features.
Authors: David C Whiteman; Mark Stickley; Peter Watt; Maria Celia Hughes; Marcia B Davis; Adèle C Green Journal: J Clin Oncol Date: 2006-07-01 Impact factor: 44.544
Authors: Limin X Clegg; Eric J Feuer; Douglas N Midthune; Michael P Fay; Benjamin F Hankey Journal: J Natl Cancer Inst Date: 2002-10-16 Impact factor: 13.506
Authors: A Tejera-Vaquerizo; M Mendiola-Fernández; A Fernández-Orland; E Herrera-Ceballos Journal: J Eur Acad Dermatol Venereol Date: 2007-12-13 Impact factor: 6.166
Authors: Adi Nosrati; Jacqueline G Berliner; Shilpa Goel; Joseph McGuire; Vera Morhenn; Juliana R de Souza; Yildiray Yeniay; Rasnik Singh; Kristina Lee; Mio Nakamura; Rachel R Wu; Ann Griffin; Barbara Grimes; Eleni Linos; Mary Margaret Chren; Roy Grekin; Maria L Wei Journal: JAMA Dermatol Date: 2017-05-01 Impact factor: 10.282
Authors: Haoming Xu; Michael A Marchetti; Stephen W Dusza; Esther Chung; Maira Fonseca; Alon Scope; Alan C Geller; Marilyn Bishop; Ashfaq A Marghoob; Allan C Halpern Journal: JAMA Dermatol Date: 2017-10-01 Impact factor: 10.282
Authors: Louisa G Gordon; Astrid J Rodriguez-Acevedo; Brian Køster; Gery P Guy; Craig Sinclair; Emilie Van Deventer; Adèle C Green Journal: JAMA Dermatol Date: 2020-04-01 Impact factor: 10.282
Authors: Alberto Julius Alves Wainstein; João Pedreira Duprat Neto; Mauro Yoshiaki Enokihara; Eduard René Brechtbühl; Felice Riccardi; Gilles Landman; Andreia Cristina de Melo; Vinicius de Lima Vazquez; Rodrigo Ramella Munhoz; Ivan Dunshee De Abranches Oliveira Santos Filho; Eduardo Bertolli; Ana Paula Drummond-Lage; Bianca Costa Soares de Sá; Luciane Botelho; Jose Higino Steck; Francisco Aparecido Belfort; Marcus Maia; Renato Marchiori Bakos; Elimar Elias Gomes; Rafael Schmerling; Flavio Cavarsan Journal: JCO Glob Oncol Date: 2020-04